Summary
Surgery has several roles in the treatment of ovarian cancer. Today, diagnosis, staging, and primary tumor debulking are probably the most established and important roles for surgery. However, surgery for patients with recurrent disease should be considered in certain circumstances after careful consideration of the risks and benefits.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Readings
Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144–153.
Greer BE, Bundy BN, Ozols RF, et al. Implications of second-look laparotomy (SLL) in the context of Gynecologic Oncology Group (GOG) protocol 158: a non-randomized comparison using an explanatory analysis [abstract]. Gynecol Oncol 2003;88:156–157.
Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159–166.
Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974–979.
Morris M, Gershenson DM, Wharton JT, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1988;34:334–338.
Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, Chi DS. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol 2004;89:306–313.
Rose PG, Nerenstone S, Brady M. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study [abstract]. Proc Am Soc Clin Oncol 2002;21:201a (abstract 802).
Rose PG, Nerenstone S, Brady MF, et al; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489–2497.
Rubin SC, Hoskins WJ, Benjamin I, Lewis JL. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 1989;34:16–19.
Tuxen MK, Strauss G, Lund B, Hansen M. The role of second-look laparotomy in the long-term survival in ovarian cancer. Ann Oncol 1997;8:643–648.
Van der Burg MEL, Van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy in the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629–634.
Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 1992;79:168–172.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Wolf, J.K., Wharton, J.T. (2006). Surgery for Ovarian Cancer. In: Eifel, P.J., Gershenson, D.M., Kavanagh, J.J., Silva, E.G. (eds) Gynecologic Cancer. M. D. Anderson Cancer Care Series, vol 5. Springer, New York, NY. https://doi.org/10.1007/0-387-28796-5_11
Download citation
DOI: https://doi.org/10.1007/0-387-28796-5_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-28794-2
Online ISBN: 978-0-387-28796-6
eBook Packages: MedicineMedicine (R0)